The report includes easily comparable data on industry value, sector ation, and five forces analysis, plus full five year industry projections for each country. It examines future problems, innovations and potential growth areas within the industry .

Scope of the Report

* Contains an Executive Summary industry values, and sector ation

* Provides textual analysis of the market 's prospects, competitive landscape and profiles of leading firms

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country. .

* Includes a five-year projection of the market

Highlights

The Scandinavian pharmaceuticals industry had a total industry value of USD 9.1 billion in 2010. Denmark was the fastest growing country with a CAGR of 4.3% over the 2006–10 period.

Sweden is the leading country among the Scandinavian countries, with industry revenues of USD 4.5 billion in 2010.

Norway is expected to lead the Pharmaceuticals in the scandinavia countries, with a value of USD 5.5 in 2015

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and industry ing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals industry consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Industry values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2009 annual average exchange rates.

Table Of Contents

TABLE OF CONTENTS
INTRODUCTION 10
What is this report about? 10
Who is the target reader? 10
Market definition 10
SCANDINAVIA PHARMACEUTICALS INDUSTRY OUTLOOK 11
Market Analysis 11
Market Revenues 12
PHARMACEUTICALS IN THE DENMARK 19
MARKET OVERVIEW 19
MARKET VALUE 20
MARKET SEGMENTATION I 21
MARKET SEGMENTATION II 22
MARKET SHARE 23
FIVE FORCES ANALYSIS 24
LEADING COMPANIES 33
MARKET FORECASTS 52
MACROECONOMIC INDICATORS 54
PHARMACEUTICALS IN NORWAY 56
MARKET OVERVIEW 56
MARKET VALUE 57
MARKET SEGMENTATION I 58
MARKET SEGMENTATION II 59
MARKET SHARE 60
FIVE FORCES ANALYSIS 61
LEADING COMPANIES 70
MARKET FORECASTS 86
MACROECONOMIC INDICATORS 88
PHARMACEUTICALS IN SWEDEN 90
MARKET OVERVIEW 90
MARKET VALUE 91
MARKET SEGMENTATION I 92
MARKET SEGMENTATION II 93
MARKET SHARE 94
FIVE FORCES ANALYSIS 95
LEADING COMPANIES 104
MARKET FORECASTS 123
MACROECONOMIC INDICATORS 125
APPENDIX 127
Data Research Methodology 127
About Datamonitor 128
Disclaimer 128

LIST OF TABLES
Table 1: Scandinavia pharmaceuticals market , revenue ($bn), 2006-14 13
Table 2: Scandinavia pharmaceuticals market , revenue ($bn), 2006-10(e) 15
Table 3: Scandinavia pharmaceuticals market projection , revenue ($bn), 2010-15 17
Table 4: Denmark pharmaceuticals industry value: USD billion, 2006-10(e) 20
Table 5: Denmark pharmaceuticals industry sector ation I:% share, by value, 2010(e) 21
Table 6: Denmark pharmaceuticals industry sector ation II: % share, by value, 2010(e) 22
Table 7: Denmark pharmaceuticals industry share: % share, by value, 2010(e) 23
Table 8: GlaxoSmithKline Plc: key facts 33
Table 9: GlaxoSmithKline Plc: key financials ($) 36
Table 10: GlaxoSmithKline Plc: key financials (£) 36
Table 11: GlaxoSmithKline Plc: key financial ratios 37
Table 12: Nycomed International Management GmbH: key facts 39
Table 13: Nycomed International Management GmbH: key financials ($) 40
Table 14: Nycomed International Management GmbH: key financials (€) 40
Table 15: Nycomed International Management GmbH: key financial ratios 41
Table 16: Orifarm Group: key facts 43
Table 17: Orifarm Group: key financials ($) 44
Table 18: Orifarm Group: key financials (DKK) 44
Table 19: Orifarm Group: key financial ratios 45
Table 20: Pfizer Inc.: key facts 47
Table 21: Pfizer Inc.: key financials ($) 49
Table 22: Pfizer Inc.: key financial ratios 49
Table 23: Denmark pharmaceuticals industry value projection : USD billion, 2010-15 52
Table 24: Denmark size of population (million), 2006-10 54
Table 25: Denmark Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 54
Table 26: Denmark Gross Domestic Product (current prices, USD billion), 2006-10 54
Table 27: Denmark inflation, 2006-10 55
Table 28: Denmark consumer price index (absolute), 2006-10 55
Table 29: Denmark exchange rate, 2006-10 55
Table 30: Norway pharmaceuticals industry value: USD billion, 2006-10(e) 57
Table 31: Norway pharmaceuticals industry sector ation I:% share, by value, 2010(e) 58
Table 32: Norway pharmaceuticals industry sector ation II: % share, by value, 2010(e) 59
Table 33: Norway pharmaceuticals industry share: % share, by value, 2010(e) 60
Table 34: AstraZeneca PLC: key facts 70
Table 35: AstraZeneca PLC: key financials ($) 72
Table 36: AstraZeneca PLC: key financial ratios 73
Table 37: GlaxoSmithKline Plc: key facts 75
Table 38: GlaxoSmithKline Plc: key financials ($) 78
Table 39: GlaxoSmithKline Plc: key financials (£) 78
Table 40: GlaxoSmithKline Plc: key financial ratios 78
Table 41: Pfizer Inc.: key facts 81
Table 42: Pfizer Inc.: key financials ($) 83
Table 43: Pfizer Inc.: key financial ratios 83
Table 44: Norway pharmaceuticals industry value projection : USD billion, 2010-15 86
Table 45: Norway size of population (million), 2006-10 88
Table 46: Norway Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 88
Table 47: Norway Gross Domestic Product (current prices, USD billion), 2006-10 88
Table 48: Norway inflation, 2006-10 89
Table 49: Norway consumer price index (absolute), 2006-10 89
Table 50: Norway exchange rate, 2006-10 89
Table 51: Sweden pharmaceuticals industry value: USD billion, 2006-10(e) 91
Table 52: Sweden pharmaceuticals industry sector ation I:% share, by value, 2010(e) 92
Table 53: Sweden pharmaceuticals industry sector ation II: % share, by value, 2010(e) 93
Table 54: Sweden pharmaceuticals industry share: % share, by value, 2010(e) 94
Table 55: AstraZeneca PLC: key facts 104
Table 56: AstraZeneca PLC: key financials ($) 106
Table 57: AstraZeneca PLC: key financial ratios 107
Table 58: Johnson and Johnson: key facts 109
Table 59: Johnson and Johnson: key financials ($) 111
Table 60: Johnson and Johnson: key financial ratios 111
Table 61: Novartis AG: key facts 114
Table 62: Novartis AG: key financials ($) 115
Table 63: Novartis AG: key financial ratios 116
Table 64: Pfizer Inc.: key facts 118
Table 65: Pfizer Inc.: key financials ($) 120
Table 66: Pfizer Inc.: key financial ratios 120
Table 67: Sweden pharmaceuticals industry value projection : USD billion, 2010-15 123
Table 68: Sweden size of population (million), 2006-10 125
Table 69: Sweden Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 125
Table 70: Sweden Gross Domestic Product (current prices, USD billion), 2006-10 125
Table 71: Sweden inflation, 2006-10 126
Table 72: Sweden consumer price index (absolute), 2006-10 126
Table 73: Sweden exchange rate, 2006-10 126

LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals market , revenue ($bn), 2006-15 12
Figure 2: Scandinavia pharmaceuticals market , revenue ($bn), 2006-10(e) 14
Figure 3: Scandinavia pharmaceuticals market projection , revenue ($bn), 2010-15 16
Figure 4: Scandinavia pharmaceuticals market , Segmentation (%), 2010 18
Figure 5: Denmark pharmaceuticals industry value: USD billion, 2006-10(e) 20
Figure 6: Denmark pharmaceuticals industry sector ation I:% share, by value, 2010(e) 21
Figure 7: Denmark pharmaceuticals industry sector ation II: % share, by value, 2010(e) 22
Figure 8: Denmark pharmaceuticals industry share: % share, by value, 2010(e) 23
Figure 9: Forces driving competition in the pharmaceuticals industry in Denmark, 2010 24
Figure 10: Drivers of buyer power in the pharmaceuticals industry in Denmark, 2010 26
Figure 11: Drivers of supplier power in the pharmaceuticals industry in Denmark, 2010 27
Figure 12: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Denmark, 2010 29
Figure 13: Factors influencing the threat of substitutes in the pharmaceuticals industry in Denmark, 2010 31
Figure 14: Drivers of degree of rivalry in the pharmaceuticals industry in Denmark, 2010 32
Figure 15: GlaxoSmithKline Plc: revenues and profitability 37
Figure 16: GlaxoSmithKline Plc: assets and liabilities 38
Figure 17: Nycomed International Management GmbH: revenues and profitability 41
Figure 18: Nycomed International Management GmbH: assets and liabilities 42
Figure 19: Orifarm Group: revenues and profitability 45
Figure 20: Orifarm Group: assets and liabilities 46
Figure 21: Pfizer Inc.: revenues and profitability 50
Figure 22: Pfizer Inc.: assets and liabilities 51
Figure 23: Denmark pharmaceuticals industry value projection : USD billion, 2010-15 53
Figure 24: Norway pharmaceuticals industry value: USD billion, 2006-10(e) 57
Figure 25: Norway pharmaceuticals industry sector ation I:% share, by value, 2010(e) 58
Figure 26: Norway pharmaceuticals industry sector ation II: % share, by value, 2010(e) 59
Figure 27: Norway pharmaceuticals industry share: % share, by value, 2010(e) 60
Figure 28: Forces driving competition in the pharmaceuticals industry in Norway, 2010 61
Figure 29: Drivers of buyer power in the pharmaceuticals industry in Norway, 2010 63
Figure 30: Drivers of supplier power in the pharmaceuticals industry in Norway, 2010 64
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Norway, 2010 66
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals industry in Norway, 2010 68
Figure 33: Drivers of degree of rivalry in the pharmaceuticals industry in Norway, 2010 69
Figure 34: AstraZeneca PLC: revenues and profitability 73
Figure 35: AstraZeneca PLC: assets and liabilities 74
Figure 36: GlaxoSmithKline Plc: revenues and profitability 79
Figure 37: GlaxoSmithKline Plc: assets and liabilities 80
Figure 38: Pfizer Inc.: revenues and profitability 84
Figure 39: Pfizer Inc.: assets and liabilities 85
Figure 40: Norway pharmaceuticals industry value projection : USD billion, 2010-15 87
Figure 41: Sweden pharmaceuticals industry value: USD billion, 2006-10(e) 91
Figure 42: Sweden pharmaceuticals industry sector ation I:% share, by value, 2010(e) 92
Figure 43: Sweden pharmaceuticals industry sector ation II: % share, by value, 2010(e) 93
Figure 44: Sweden pharmaceuticals industry share: % share, by value, 2010(e) 94
Figure 45: Forces driving competition in the pharmaceuticals industry in Sweden, 2010 95
Figure 46: Drivers of buyer power in the pharmaceuticals industry in Sweden, 2010 97
Figure 47: Drivers of supplier power in the pharmaceuticals industry in Sweden, 2010 98
Figure 48: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Sweden, 2010 100
Figure 49: Factors influencing the threat of substitutes in the pharmaceuticals industry in Sweden, 2010 102
Figure 50: Drivers of degree of rivalry in the pharmaceuticals industry in Sweden, 2010 103
Figure 51: AstraZeneca PLC: revenues and profitability 107
Figure 52: AstraZeneca PLC: assets and liabilities 108
Figure 53: Johnson and Johnson: revenues and profitability 112
Figure 54: Johnson and Johnson: assets and liabilities 113
Figure 55: Novartis AG: revenues and profitability 116
Figure 56: Novartis AG: assets and liabilities 117
Figure 57: Pfizer Inc.: revenues and profitability 121
Figure 58: Pfizer Inc.: assets and liabilities 122
Figure 59: Sweden pharmaceuticals industry value projection : USD billion, 2010-15 124


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.